Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 187

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Nanomedicines for Cancer Therapy: An Update of FDA Approved and Those under Various Stages of Development

Open access
Pillai, Gopalakrishna·2014·SOJ Pharmacy & Pharmaceutical Sciences

Abstract

Nanomaterials, with their size range (1-100 nm) that corresponds to basic biological materials such as DNA, vastly increased surface area (1000 m 2 /g) and unique mechanical, electronic, photonic and magnetic properties are projected to have a wide range of applications from drug and gene delivery to biomedical imaging and more recently to personalized medicine.The major advantages of using nanomaterials as a carrier for anticancer agents are the possibility of targeted delivery to the tumor, tumor imaging, their ability to hold thousands of molecules of a drug and also their ability to overcome solubility, stability and resistance issues.Currently, there are several nanotechnology-enabled diagnostic and therapeutic agents undergoing clinical trials and a few are already approved by the FDA.Targeted delivery of anticancer agents is achieved by exploiting a unique characteristic of the tumor cells called "the Enhanced Permeation and Retention Effect (EPR effect).In addition to this passive targeting based mainly on size, the nanoparticle surface may be modified with a variety of ligands that would interact with specific receptors over-expressed on the surface of the tumor cells, thus imparting specificity for active targeting.Site-specific release of a drug contained in a nanoparticulate system by the application of external stimuli such as hyperthermia to a thermosensitive device is another innovative strategy for targeted delivery.This review provides an update on the FDA approved cancer nanomedicines such as Abraxane, Doxil, daunoxome, Oncaspar, DepoCyt and those in nanoplatforms that have reached an advanced stage of clinical development utilizing liposomes, lipid nanoparticles, lipoplexes, albumin nanospheres, thermosensitive devices, micelles and gold nanoparticles.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15226/2374-6866/1/2/00109

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 187

Metadata

Authors
Pillai, G.
Venue
SOJ Pharmacy & Pharmaceutical Sciences
Published
2014
ISSN
2374-6866 (ISSN-L)
OpenAlex
W2168127523
Cited by
187
References
6
FWCI
5.95
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nanomedicines for Cancer Therapy: An Update of FDA Approved and Those under Various Stages of Development. https://app.cochat.ai/papers/10.15226/2374-6866/1/2/00109
The paper
Pillai, G. (2014). Nanomedicines for Cancer Therapy: An Update of FDA Approved and Those under Various Stages of Development. SOJ Pharmacy & Pharmaceutical Sciences. https://doi.org/10.15226/2374-6866/1/2/00109

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.